Important sources of variability in clinical studies of neutralizing antibodies against interferon beta

Hurwitz, Barrie J.

doi:10.1016/j.jns.2008.05.004

Cited by 5 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-beta is a cytokine naturally expressed in response to viral infections [22], however, its mechanism of action in MS is not completely understood, but it has been speculated that, besides its immunomodulatory properties, the efficacy of IFN-beta may be related to its antiviral properties [23]. However, it has been observed consistently that a proportion of patients (2% to 47%) develop NAbs directed against IFN beta as a consequence of the treatment [24], [25]. In our study, the 32.8% of MS patients was positive for NAbs; as NAbs are associated with a loss of efficacy of IFN-beta treatment and a reduced bioavailability, they appeared at any time of the four scheduled visits and while some NAbs positive patients remained positive along the IFN-beta treatment, others patients became negative, we decided to evaluate the variation of the anti-HHV-6A/B IgG titers only in an homogenous cohort of MS patients without NAbs.…”

Section: Discussionmentioning

confidence: 99%

Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo analyze the titers of the IgG and IgM antibodies against human herpesvirus 6A/B (HHV-6A/B) in multiple sclerosis (MS) patients treated with different disease modified therapies (DMTs) along two-years of follow-up.MethodsWe collected 2163 serum samples from 596 MS; for 301 MS patients a 2-years follow-up was performed. Serum samples of 337 healthy controls were also analyzed. Anti-HHV-6A/B IgG and IgM were analyzed by ELISA (Panbio).ResultsWe found that 129/187 (69.0%) MS patients with a decrease of the anti-HHV-6A/B IgG titers after 2-years with DMTs were free of relapses and progression vs. 46/113 (40.7%) of MS patients with an increase of the anti-HHV-6A/B IgG titers (p = 0.0000015); the higher significance was found for natalizumab. Furthermore, we found that anti-HHV-6A/B IgG titers reached their highest value two weeks before the relapse (p = 0.0142), while the anti-HHV-6A/B IgM titers reached their highest value one month before the relapse (p = 0.0344).ConclusionThe measurement of the anti-HHV-6A/B IgG titers could be a good biomarker of clinical response to the different DMTs. The increase of the anti-HHV-6A/B IgG and IgM titers predicts the upcoming clinical relapses. However, further longitudinal studies are needed to validate these results.

show abstract